دورية أكاديمية
Implementing MyChoice® CDx HRD testing for the Nordics: lessons from 2021 to 2023.
| العنوان: | Implementing MyChoice® CDx HRD testing for the Nordics: lessons from 2021 to 2023. |
|---|---|
| المؤلفون: | Korsholm LM; Center for Genomic Medicine, Copenhagen University Hospital - Rigshospitalet, 2100 Copenhagen, Denmark., Broecker V; Department of Clinical Pathology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden., Mirza MR; Department of Oncology, Rigshospitalet, Copenhagen University Hospital - Rigshospitalet, 2100 Copenhagen, Denmark., Rossing M; Center for Genomic Medicine, Copenhagen University Hospital - Rigshospitalet, 2100 Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. caroline.maria.rossing@regionh.dk. |
| المصدر: | Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2024 Mar 14; Vol. 63, pp. 70-75. Date of Electronic Publication: 2024 Mar 14. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Medical Journals Sweden AB Country of Publication: Sweden NLM ID: 8709065 Publication Model: Electronic Cited Medium: Internet ISSN: 1651-226X (Electronic) Linking ISSN: 0284186X NLM ISO Abbreviation: Acta Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2024- : [Uppsala, Sweden] : Medical Journals Sweden AB Original Publication: Stockholm, Sweden : Acta Oncologica, [1987- |
| مواضيع طبية MeSH: | Ovarian Neoplasms*/diagnosis , Ovarian Neoplasms*/genetics , Ovarian Neoplasms*/drug therapy , Antineoplastic Agents*/therapeutic use, Female ; Humans ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Finland ; Norway |
| مستخلص: | Background: Assessment of homologous recombinant deficient (HRD) phenotypes is key for managing Poly (ADP-ribose) polymerase inhibitor (PARPi) treatment. To accommodate the need for a validated HRD platform and enhance targeted treatment of ovarian cancer patients, a Nordic core facility for the myChoice® CDx platform was established in Denmark. Materials and Methods: Comparative calculations and statistics are based on information from test requisitions and results (Genome Instability Score [GIS], BRCA status and combined HRD status) obtained from ovarian and breast cancer samples submitted for HRD-testing by myChoice® CDx through the Nordic core facility in the 2-year period. Results: Copenhagen University Hospital received 1,948 requisitions during the 2-year period. Conclusive results were obtained in 89% of the tests, while 7% were inconclusive due to the lack of GIS and 4% were not able to be analysed. Comparing the conclusive HRD status results across countries, Sweden had the highest percentage of HRD positives (38%) compared to Denmark, Norway, and Finland (28-32%). Interpretation: The myChoice® CDx Nordic core facility has been well received among the Nordic countries and provides new insights on the influence of national guidelines on HRD testing. Overall, we experienced an efficient turnaround time and a high fraction of conclusive results. Interestingly, prior somatic BRCA testing is redundant when assessing HRD status through myChoice® CDx test since somatic BRCA screening is already a significant component of the myChoice® CDx test. Thus, it should be considered to omit prior somatic BRCA testing to ensure a rationalised HRD diagnostic flow optimised for clinical use. |
| المشرفين على المادة: | 0 (Poly(ADP-ribose) Polymerase Inhibitors) 0 (Antineoplastic Agents) |
| تواريخ الأحداث: | Date Created: 20240314 Date Completed: 20240315 Latest Revision: 20240315 |
| رمز التحديث: | 20240315 |
| DOI: | 10.2340/1651-226X.2024.34139 |
| PMID: | 38482597 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1651-226X |
|---|---|
| DOI: | 10.2340/1651-226X.2024.34139 |